文献速递物质与行为成瘾

GLP-1受体激动剂与酒精及物质使用障碍相关住院风险的关联

Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

结果显示GLP-1暴露与两类住院率降低相关,酒精使用障碍的关联在停药后182天内仍存在,此后不再明显。

要点

  • GLP-1暴露期酒精使用障碍相关住院率低于同一人未暴露期(RR 0·55,95%CI 0·43-0·70)。
  • 酒精使用障碍的住院率降低在停药后1-182天仍存在(0·70,0·50-0·98),183-364天不再明显(1·07,0·71-1·63)。
  • 停药后应监测物质使用情况。

核心结论

  • GLP-1受体激动剂治疗与酒精使用障碍和物质使用障碍相关住院率降低相关,酒精使用障碍的关联延续至停药后182天内。

研究设计与样本

  • 采用固定效应泊松回归模型估计住院率比(RR),比较同一人GLP-1受体激动剂或DPP-4抑制剂暴露期及两个暴露后窗口(1-182天、183-364天)与未暴露期。

主要发现

  • 1559例(0·9%)至少有1次酒精使用障碍相关住院,2008例(1·2%)至少有1次物质使用障碍相关住院。
  • 接受GLP-1受体激动剂者中308例(0·7%)至少有1次酒精相关住院,444例(1·1%)至少有1次物质使用相关住院;444例中记录的1447次物质使用障碍相关住院有957次(66·1%)归因于酒精使用障碍。
  • 与同一人未暴露期相比,GLP-1暴露与酒精使用障碍相关住院率降低(RR 0·55,95%CI 0·43-0·70)及物质使用障碍相关住院率降低(0·61,0·50-0·74)相关。
  • 物质使用障碍在停药后1-182天(0·79,0·61-1·02)和183-364天(0·89,0·63-1·26)均无统计学显著的降低关联;DPP-4抑制剂未见一致的住院率降低。

关键数值与推荐

  • 酒精使用障碍停药后1-182天RR 0·70(95%CI 0·50-0·98),183-364天RR 1·07(0·71-1·63)。
  • 物质使用障碍停药后1-182天RR 0·79(0·61-1·02),183-364天RR 0·89(0·63-1·26)。

临床怎么用

  • 对接受GLP-1受体激动剂治疗的2型糖尿病患者,可关注其酒精及物质使用情况。
  • 停用GLP-1受体激动剂后仍应监测物质使用,尤其是酒精使用障碍患者。

局限性

  • 为观察性研究,不能确立因果关系。
  • 仅基于瑞典登记库数据,缺乏族裔数据,外推需谨慎。
  • 研究对象为2型糖尿病患者,未涉及无糖尿病人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence suggests that GLP-1 receptor agonists might reduce substance use across different substance use disorders. However, data on substance use-related outcomes after GLP-1 discontinuation are absent. This study aimed to investigate the risk of alcohol and substance use-related hospitalisations during and after exposure to GLP-1 receptor agonists. METHODS: This within-individual observational study used Swedish registers to identify residents of Stockholm County with a first registered diagnosis of type 2 diabetes between Jan 1, 2005, and Dec 31, 2024 who had received GLP-1 receptor agonists and, for comparison, DPP-4 inhibitors. Active follow‑up started on Jan 1, 2015, or on the date of the first registered diabetes diagnosis, whichever occurred later. Patients were followed up until the end of the observation period (Dec 31, 2024). The main outcomes were hospitalisations related to alcohol use disorder and substance use disorder (which included the alcohol use disorder-related events). Fixed-effects Poisson regression models were used to estimate rate ratios (RRs) of hospitalisations, comparing periods of GLP-1 receptor agonist or DPP-4 inhibitor exposure and two post-exposure windows (days 1-182 and 183-364) with unexposed periods in the same individuals. People with lived experience were not involved in the study. FINDINGS: 167 026 individuals with type 2 diabetes (mean age 63·98 years [SD 13·77]; median age 65·00 years [IQR 55·00-74·00]; 96 133 [57·6%] males and 70 893 [42·4%] females) were included in the study. Ethnicity data were unavailable. 1559 (0·9%) individuals had at least one alcohol use disorder-related hospitalisation and 2008 (1·2%) had at least one substance use disorder-related hospitalisation. 41 109 (24·6%) individuals received GLP-1 receptor agonists during the study period, and 23 666 (14·2%) received DPP-4 inhibitors. 308 (0·7%) of those receiving GLP-1 receptor agonists had at least one alcohol-related hospitalisation during the observational period, and 444 (1·1%) had at least one substance use-related hospitalisation; 957 (66·1%) of the 1447 substance use disorder-related hospitalisations recorded in these 444 individuals were attributed to alcohol use disorder. GLP-1 exposure was associated with lower rates of hospitalisations related to alcohol use disorder (RR 0·55, 95% CI 0·43-0·70) and substance use disorder (0·61, 0·50-0·74) compared with unexposed periods for the same individuals. For individuals with alcohol use disorder, the association with hospitalisation rate reduction persisted during days 1-182 after discontinuation of GLP-1 receptor agonists (0·70, 0·50-0·98) but was no longer evident during days 183-364 after discontinuation (1·07, 0·71-1·63); for substance use disorder, there were no statistically significant associations with reduction after discontinuation of GLP-1 receptor agonists (days 1-182: 0·79, 0·61-1·02; days 183-364: 0·89, 0·63-1·26). DPP-4 inhibitors were not associated with consistent rate reductions. INTERPRETATION: GLP-1 receptor agonist treatment was associated with lower rates of hospitalisation in individuals with alcohol use disorder and substance use disorder. This association extended into the first 182 days after discontinuation for alcohol use disorder but not for substance use disorder. Findings support clinical monitoring of substance use when GLP-1 receptor agonist treatment is stopped. FUNDING: Forte, Karolinska Institutet, and Region Stockholm.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bach P, Franck J, Hällgren J, et al. Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study. Lancet Psychiatry. 2026. PMID: 42456704. doi:10.1016/S2215-0366(26)00172-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。